Neoseptin 3
目录号 : GC33405
Neoseptin3是Toll样受体4/髓样分化因子2(mTLR4/MD-2)的激动剂，其EC50值为18.5μM。
Cas No.:1622863-21-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
|
Kinase experiment: |
HEK293T cells are transfected with an NF-κB-dependent luciferase reporter plasmid and clones with stable expression are selected by culture in DMEM containing puromycin. Cells are cotransfected with constructs for mouse or human TLR4 plus mouse or human MD-2, and 2 d later are stimulated with 50 μM Neoseptin-3 or 1 μg/mL LPS for 6 h. Cells are lysed, and luciferase activity is measured[1]. |
|
Cell experiment: |
Cells are seeded onto 96-well plates at 1×105 cells per well and stimulated with Neoseptin-3 [dissolved in DMSO; final DMSO concentrations (≤0.2%) are kept constant in all experiments] for 4 h. Mouse TNFα, IL-6, or IFN-β, or human TNFα in the supernatants are measured by ELISA kits according to the manufacturer’s instructions. Unless otherwise indicated, mouse cells are from wild-type C57BL/6J mice[1]. |
|
References: [1]. Wang Y, et al. TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS. Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):E884-93. |
|
Neoseptin 3 is a Toll-like receptor 4/myeloid differentiation factor 2 (mTLR4/MD-2) agonist with an EC50 of 18.5 μM.
Neoseptin 3 is a Toll-like receptor 4/myeloid differentiation factor 2 (mTLR4/MD-2) agonist with an EC50 of 18.5 μM. Neoseptin-3 induces TNFα production by macrophages in a concentration-dependent manner. Neoseptin-3 induces phosphorylation of IκB kinases α (IKKα), IKKβ, p38, c-Jun N-terminal kinase (JNK), and ERK, and degradation of IκBα, consistent with activation of MAPK and canonical NF-κB signaling. TANK-binding kinase 1 (TBK1) and IRF3 phosphorylation also increase in response to Neoseptin-3[1].
[1]. Wang Y, et al. TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS. Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):E884-93.
| Cas No. | 1622863-21-1 | SDF | |
| Canonical SMILES | CC(C)(C)OC([C@H](CCC1=CC=CC=C1)NC(C2=CC(CCC3=CC=C(O)C=C3)=C(N)C=C2)=O)=O | ||
| 分子式 | C29H34N2O4 | 分子量 | 474.59 |
| 溶解度 | DMSO: ≥ 100 mg/mL (210.71 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1071 mL | 10.5354 mL | 21.0708 mL |
| 5 mM | 0.4214 mL | 2.1071 mL | 4.2142 mL |
| 10 mM | 0.2107 mL | 1.0535 mL | 2.1071 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。